

HAW

DOCKET NO.: CELL-0316/PA553-USW01  
PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Mark Ian Christie, et al.

Application No.: 10/580,164

Filing Date: May 18, 2006

For: **METHOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS BY  
INHIBITING IL-17 ACTIVITY**

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

DATE OF DEPOSIT: *December 20, 2006*

I HEREBY CERTIFY THAT THIS PAPER IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID, ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

TYPED NAME: Elizabeth A. McLoud

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☒ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified

application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☐ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☐ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers **34 - 118** listed on the attached Form PTO-1449 are enclosed herewith.

- ☒ Copies of reference numbers **1 - 33** on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for


which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.

☐ The relevance of those listed references which are not in the English language is as follows:

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: *December 20, 2006*

  
\_\_\_\_\_  
Jane E. Inglese  
Registration No. 48,444

WOODCOCK WASHBURN LLP  
Cira Centre  
2929 Arch Street, 12th Floor  
Philadelphia, PA 19104-2891  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0316/ PA553-USw01	Application No. 10/580,164
	Applicant Mark Ian Christie, et al.	
	Filing Date May 18, 2006	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	1	4,439,196	03/27/84	Higuchi	604	890
	2	4,447,224	05/08/84	DeCant, Jr., et al.	604	67
	3	4,447,233	05/08/84	Mayfield	604	152
	4	4,475,196	10/02/84	La Zor	371	29
	5	4,486,194	12/04/84	Ferrara	604	897
	6	4,487,603	12/11/84	Harris	604	152
	7	4,596,556	06/24/86	Morrow, et al.	604	70
	8	4,790,824	12/13/88	Morrow, et al.	604	143
	9	4,941,880	07/17/90	Burns	604	143
	10	4,946,778	08/07/90	Ladner, et al.	435	69.6
	11	4,980,286	12/25/90	Morgan, et al.	435	172.3
	12	5,064,413	11/12/91	McKennon, et al.	604	70
	13	5,219,996	06/15/93	Bodner, et al.	530	387.3
	14	5,223,409	06/29/93	Ladner, et al.	435	69.7
	15	5,312,335	05/17/94	McKinnon, et al.	604	72
	16	5,383,851	01/24/95	McKinnon, Jr., et al.	604	68
	17	5,399,163	03/21/95	Peterson, et al.	604	68
	18	5,403,484	04/04/95	Ladner, et al.	435	235.1
	19	5,427,908	06/27/95	Dower, et al.	435	5
	20	5,516,637	05/14/96	Huang, et al.	435	6

**EXAMINER****DATE CONSIDERED**

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0316/ PA553-USw01	Application No. 10/580,164
	Applicant Mark Ian Christie, et al.	
	Filing Date May 18, 2006	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	21	5,571,698	11/05/96	Ladner, et al.	435	69.7
	22	5,580,717	12/03/96	Dower, et al.	435	5
	23	5,585,089	12/17/96	Queen, et al.	424	133.1
	24	5,658,727	08/19/97	Barbas, et al.	435	6
	25	5,677,425	10/14/97	Bodner, et al.	530	387.1
	26	5,698,426	12/16/97	Huse	435	172.3
	27	5,733,743	03/31/98	Johnson, et al.	435	69.1
	28	5,738,996	04/14/98	Hodges, et al.	435	7.1
	29	5,750,753	05/12/98	Kimae, et al.	556	440
	30	5,780,225	07/14/98	Wigler, et al.	435	6
	31	5,807,683	09/15/98	Brenner	435	7.1
	32	5,821,047	10/13/98	Garrard, et al.	435	5
	33	5,969,108	10/19/99	McCafferty, et al.	530	387.3

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office				Docket No. CELL-0316/ PA553-USw01		Application No. 10/580,164	
				Applicant Mark Ian Christie, et al.			
				Filing Date May 18, 2006		Group Not Yet Assigned	
				Confirmation No. Not Yet Assigned			
<b>FOREIGN PATENT DOCUMENTS</b>							
Examiner Initial		Document No.	Date	Country	Translation		
					YES	NO	
	34	WO 86/01533 A1	03/13/86	PCT			
	35	WO 90/02809 A1	03/22/90	PCT			
	36	WO 91/10737 A1	07/25/91	PCT			
	37	WO 92/01047 A1	01/23/92	PCT			
	38	WO 92/02551 A1	02/20/92	PCT			
	39	WO 92/18619 A1	10/29/92	PCT			
	40	WO 92/22853 A1	12/23/92	PCT			
	41	WO 93/08829 A1	05/13/93	PCT			
	42	WO 93/11236 A1	06/10/93	PCT			
	43	WO 95/15982 A2	06/15/95	PCT			
	44	WO 95/20401 A1	08/03/95	PCT			
	45	WO 98/25971 A1	06/18/98	PCT			
	46	WO 99/15549 A3	04/01/99	PCT			
	47	WO2004/042009 A3	05/21/04	PCT			
	48	WO2005/003169 A2 Equiv. to GB 2004/002810	01/13/05	PCT			
	49	WO2005/003170 A3 equiv. to GB2004/002870	01/13/05	PCT			

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0316/ PA553-USw01	Application No. 10/580,164
	Applicant Mark Ian Christie, et al.	
	Filing Date May 18, 2006	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned

### FOREIGN PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	50	WO2005/003171A3 equiv. to GB2004/002871	01/13/05	PCT		
	51	0 392 745 B1	11/02/94	EP		
	52	0 948 544 B1	05/02/03	EP		

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0316/ PA553-USw01	Application No. 10/580,164
		Applicant Mark Ian Christie, et al.	
		Filing Date May 18, 2006	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	53	Aggarwal, S., et al., "Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17," <i>J. of Biological Chem.</i> , <b>2003</b> , 278(3), 1910-1914	
	54	Ames, R.S., et al., "Conversion of murine Fabs isolated from a combinatorial phage display library to full length immunoglobulins," <i>J. Immunol. Methods</i> , <b>1995</b> , 184, 177-186	
	55	Babcock, J.S., et al., "A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1996</b> , 93, 7843-7848	
	56	Baker, D., et al., "Induction of chronic relapsing experimental allergic encephalomyelitis in biozzi mice," <i>Journal of Neuroimmunology</i> , <b>1990</b> , 28, 261-270	
	57	Bollard, C., et al., "Adapting a transforming growth factor $\beta$ -related tumor protection strategy to enhance antitumor immunity," <i>Blood</i> , <b>2002</b> , 99(9), 3179-3187	
	58	Brinkman, U., et al., "Phage display of disulfide-stabilized Fv fragments," <i>J. Immunol. Methods</i> , <b>1995</b> , 182, 41-50	
	59	Burns, J.A., et al., "Selective reduction of disulfides by tris(2-carboxyethyl)phosphine," <i>J. Org. Chem.</i> , <b>1991</b> , 56, 2648-2650	
	60	Burton, D.R., et al., "Human antibodies for combinatorial libraries," <i>Advances in Immunology</i> , <b>1994</b> , 57, 191-280	
	61	Carrell, T., et al., "A novel procedure for the synthesis of libraries containing small organic molecules," <i>Angew. Chem Int. Ed. Engl.</i> , <b>1994</b> , 33(20), 2059, 2061	
	62	Chapman, A.P., "PEGylated antibodies and antibody fragments for improved therapy: a review," <i>Advanced Drug Delivery Reviews</i> , <b>2002</b> , 54, 531-545	
	63	Cho, C.Y., et al., "An unnatural biopolymer," <i>Science</i> , <b>1993</b> , 261, 1303-1305	
	64	Chung, D.R., et al., "CD4 <sup>+</sup> T cells regulate surgical and postinfectious adhesion formation," <i>J. Exp Med.</i> , <b>2002</b> , 195(11), 1471-1478	
	65	Cole, S.P.C., et al., "The EBV-hybridoma technique and its application to human lung cancer," <i>Monoclonal Antibodies and Cancer Therapy</i> , <b>1985</b> , 77-96	
	66	Coprav, S., et al., "Deficient p75 low-affinity neurotrophin receptor expression exacerbates experimental allergic encephalomyelitis in C57/BL6 mice," <i>Journal of Neuroimmunology</i> , <b>2004</b> , 148, 41-53	

EXAMINER	DATE CONSIDERED
----------	-----------------



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0316/ PA553-USw01	Application No. 10/580,164
		Applicant Mark Ian Christie, et al.	
		Filing Date May 18, 2006	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	67	Cull, M.G., et al., "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the <i>lac</i> repressor," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1992</b> , 89, 1865-1869	
	68	Cwirla, S.E., et al., "Peptides on phage: a vast library of peptides for identifying ligands," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1990</b> , 87, 6378-6382	
	69	Devlin J.J., et al., "Random peptide libraries: a source of specific protein binding molecules," <i>Science</i> , <b>1990</b> , 249, 404-406	
	70	DeWitt, S.H., et al., "'Diversomers': an approach to nonpeptide, nonoligomeric chemical diversity," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1993</b> , 90, 6909-6913	
	71	Dubowchik, G.M., et al., "Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs," <i>Pharmacology and Therapeutics</i> , <b>1999</b> , 83, 67-123	
	72	Dumont, F.J., "IL-17 cytokine/receptor families: emerging targets for the modulation of inflammatory responses," <i>Expert Opin. Ther. Patents</i> , <b>2003</b> , 13(3), 287-303	
	73	Ellison, D., et al., "Photoreduction of monoclonal antibodies for conjugation and fragmentation," <i>Biotechniques</i> , <b>2000</b> , 28, 324-326	
	74	Erb, E., et al., "Recursive deconvolution of combinatorial chemical libraries," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1994</b> , 91, 11422-11426	
	75	Felici, F., "Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent expression vector," <i>J. Mol. Biol.</i> , <b>1991</b> , 222, 301-310	
	76	Ferreti, F., et al., "IL-17, produced by lymphocytes and neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a possible trigger," <i>Journal of Immunology</i> , <b>2003</b> , 170, 2106-2112	
	77	Fodor, S.P.A., et al., "Multiplexed biochemical assays with biological chips," <i>Nature</i> , <b>1993</b> , 364, 555-556	
	78	Fossiez, F., et al., "Interleukin-17," <i>Int. Rev. Immunol.</i> <b>1998</b> , 16, 541-551	
	79	Gallop, M.a., et al., "Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries," <i>J. Med. Chem.</i> , <b>1994</b> , 37(9), 1233	
	80	Getz, E.B., et al., "A comparison between the sulfhydryl reductants tris(2-carboxyethyl)phosphine and dithiothreitol for use in protein biochemistry," <i>Analytical Biochemistry</i> , <b>1999</b> , 273, 73-80	

EXAMINER	DATE CONSIDERED
----------	-----------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0316/ PA553-USw01	Application No. 10/580,164
	Applicant Mark Ian Christie, et al.	
	Filing Date May 18, 2006	Group Not Yet Assigned
	Confirmation No. Not Yet Assigned	

**NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	<b>81</b>	Goodin, D.S. et al., "Disease modifying therapies in multiple sclerosis; Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines," <i>American Academy of Neurology</i> , <b>2002</b> , 58(2), 169-178
	<b>82</b>	Han, J.C., et al., "A procedure for quantitative determination of tris(2-carboxyethyl)phosphine, an orderless reducing agent more stable and effective than dithiothreitol," <i>Analytical Biochemistry</i> , <b>1994</b> , 220, 5-10
	<b>83</b>	Hellstrom, K.E., et al., "Antibodies for drug delivery," <i>Controlled Drug Delivery</i> , 2 <sup>nd</sup> Ed, Robinson, J.R., et al. (Eds.), <b>1987</b> , 623-653
	<b>84</b>	Hoshida, T. et al., "Gene therapy for pancreatic cancer using an adenovirus vector encoding soluble flt-1 vascular endothelial growth factor receptor," <i>Pancreas</i> , <b>2002</b> , 25(2), 111-121
	<b>85</b>	Houghten, R.A., et al., "The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides," <i>Bio/Techniques</i> , <b>1992</b> , 13(3), 412-421
	<b>86</b>	Humphreys, D.P., et al., "A plasmid system for optimization of Fab' production in <i>Escherichia coli</i> ; importance of balance of heavy chain and light chain synthesis," <i>Protein Expression and Purification</i> , <b>2002</b> , 26, 309-320
	<b>87</b>	Ikuno, Y., "An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor $\alpha$ receptor," <i>Invest Ophthalmol Vis. Sci.</i> , <b>2002</b> , 43(7), 2406-2411
	<b>88</b>	Jacoby, D.R., et al., "Hybrid vectors: a new generation of virus-based vectors designed to control the cellular fate of delivered genes," <i>Gene Therapy</i> , <b>1997</b> , 4, 1282-1283
	<b>89</b>	Kettleborough, C.A., et al., "Isolation of tumor cell-specific single-chain Fv from immunized mice using phage-antibody libraries and the re-construction of whole antibodies from these antibody fragments," <i>Eur. J. Immunol</i> , <b>1994</b> , 24, 952-958
	<b>90</b>	Kochanek, S., "High-capacity adenoviral vectors for gene transfer and somatic gene therapy," <i>Human Gene Therapy</i> , <b>1999</b> , 10, 2451-2459
	<b>91</b>	Köhler, G., et al., "Continuous cultures of fused cells secreting antibody of predefined specificity," <i>Nature</i> , <b>1975</b> , 256, 495-497
	<b>92</b>	Kozbor, D., et al., "The production of monoclonal antibodies from human lymphocytes," <i>Immunology Today</i> , <b>1983</b> , 4(3), 72-79
	<b>93</b>	Lam, K.S., "Application of combinatorial library methods in cancer research and drug discovery," <i>Anti-cancer Drug Des.</i> , <b>1997</b> , 12, 145-167

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. CELL-0316/ PA553-USw01		Application No. 10/580,164
	Applicant Mark Ian Christie, et al.		
	Filing Date May 18, 2006		Group Not Yet Assigned
	Confirmation No. Not Yet Assigned		
<b>NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	94	Lam., K.S., et al., "A new type of synthetic peptide library for identifying ligand-binding activity," <i>Nature</i> , <b>1991</b> , 354, 82-84	
	95	Leach, S.J., et al., "The electrolytic reduction of proteins," <i>Div. Protein Chem.</i> , <b>1965</b> , 4(1), 23-27	
	96	Lee, E.J., et al., "Adenovirus-directed expression of dominant negative estrogen receptor induces apoptosis in breast cancer cells and regression," <i>Mol. Med.</i> , <b>2001</b> , 7(11), 773-782	
	97	Lock, C., et al., "Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis," <i>Nature Medicine</i> , <b>2002</b> , 8(5), 500-508	
	98	Lubberts, E., et al., "IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis," <i>J. Immunol</i> , <b>2001</b> , 167, 1004-1013	
	99	Matuszewicz, D., et al., "Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis," <i>Multiple Sclerosis</i> , <b>1999</b> , 5, 101-104	
	100	Miller, D., et al., "use of retroviral vectors for gene transfer and expression," <i>Meth. Enzymol</i> , <b>1993</b> , 217, 581-599	
	101	Milstein, C., et al., "Hybrid hybridomas and their use in immunohistochemistry," <i>Nature</i> , <b>1983</b> , 305, 537-539	
	102	Pelidou, S.-H., et al., "Enhancement of acute phase and inhibition of chronic phase of experimental autoimmune neuritis in Lewis rats by intranasal administration of recombinant mouse interleukin 17: potential immunoregulatory role," <i>Experimental Neurology</i> , <b>2000</b> , 163, 2000-2005	
	103	Persic, L., et al., "An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries," <i>Gene</i> , <b>1997</b> , 187, 9-18	
	104	Reynolds, P.N., et al., "Chimeric viral vectors – the best of both worlds?," <i>Molecular Medicine Today</i> , <b>1999</b> , 25-31	
	105	Robbins, P.D., et al., "Viral vectors for gene therapy," <i>Pharmacol Ther.</i> , <b>1998</b> , 80(1), 35-47	
	106	Rüegg, U.T., et al., "Reductive cleavage of cystine disulfides with tributylphosphine," <i>Methods in Enzymology</i> , <b>1977</b> , 47, 111-126	

EXAMINER	DATE CONSIDERED
----------	-----------------

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. CELL-0316/ PA553-USw01	Application No. 10/580,164
		Applicant Mark Ian Christie, et al.	
		Filing Date May 18, 2006	Group Not Yet Assigned
		Confirmation No. Not Yet Assigned	
<b>NON-PATENT DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	107	Scott, J.K., et al., "Searching for peptide ligands with an epitope library," <i>Science</i> , <b>1990</b> , 249, 386-390	
	108	Seitz, U., et al., "Preparation and evaluation of the rhenium-188-labelled anti-NCA antigen monoclonal antibody BW 250/183 for radioimmunotherapy of leukaemia," <i>Euro. J. Nuclear Medicine</i> , <b>1999</b> , 26(10), 1265-1273	
	109	Singh, R., et al., "Reagents for rapid reduction of disulfide bonds," <i>Methods in Enzymology</i> , <b>1995</b> , 251, 167-173	
	110	't Hart, B.A., et al., "The use of animal models to investigate the pathogenesis of neuroinflammatory disorders of the central nervous system," <i>Current Opinion in Neurology</i> , <b>2003</b> , 16, 375-383	
	111	Thorpe, P.E., et al., "The preparation and cytotoxic properties of antibody-toxin conjugates," <i>Immunol Rev</i> , <b>1982</b> , 62, 119-158	
	112	Traunecker, A., et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>EMBO J.</i> , <b>1991</b> , 10(12), 3655-3659	
	113	Verma, R., et al., "Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems," <i>Journal of Immunological Methods</i> , <b>1998</b> , 216, 165-181	
	114	Wu, G.Y., et al., "Receptor-mediated <i>in vitro</i> gene transformation by a soluble DNA carrier system," <i>J. Biol. Chem.</i> , <b>1987</b> , 262(10), 4429-4432	
	115	Yao, Z., et al., "Molecular characterization of the human interleukin (IL)-17 receptor," <i>Cytokine</i> , <b>1997</b> , 9(11), 794-800	
	116	Yao, Z./ et al., "Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor," <i>Immunity</i> , <b>1995</b> , 3, 811-821	
	117	Yao, Z., et al., "Human IL-17: a novel cytokine derived from T cells," <i>Journal of Immunology</i> , <b>1995</b> , 155, 5483-5486	
	118	Zuckermann, R.N., et al., "Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse <i>N</i> -(substituted)glycine peptoid library," <i>J. Med. Chem.</i> <b>1994</b> , 37, 2678-2685	

EXAMINER	DATE CONSIDERED
----------	-----------------